Eisai and Biogen’s Alzheimer’s Therapy Leqembi Receives Marketing Approval in Hong Kong
Eisai Co., Ltd, a Japanese pharmaceutical company, along with its co-development partner Biogen Inc. (NASDAQ:...
NASDAQ: BIIB
Eisai and Biogen Launch Alzheimer’s Drug Leqembi in China Following Market Approval
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, in partnership with Biogen Inc. (NASDAQ:...
Bio-Thera Solutions’ BAT1806 Receives Positive CHMP Recommendation for EU Approval
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that the Committee for Medicinal Products for...
Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan
Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of...
Biogen Discontinues Aduhelm Development, Redirects Focus to Other Alzheimer’s Therapies
Biogen (NASDAQ: BIIB) has announced its decision to discontinue the development and commercialization of its...
Sandoz Launches Biosimilar Natalizumab in Germany, Challenging Biogen’s Tysabri
Sandoz, a division of Novartis and a leader in generic drugs and biosimilars headquartered in...
CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment
Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...
C4 Therapeutics Outlines 2024 Focus Amid 30% Workforce Reduction, Prioritizes Key Oncology Trials
C4 Therapeutics (NASDAQ: CCCC), a leader in protein degradation, announced this week its strategic focus...
Biogen’s BIIB080 Shows Promise in Phase Ib Trial for Mild Alzheimer’s Disease
Biogen (NASDAQ: BIIB) has released preliminary findings from a Phase Ib trial for BIIB080, a...
Bio-Thera Solutions’ BAT1806 Receives US FDA Approval as Biosimilar to Actemra/RoActemra
Bio-Thera Solutions Ltd (SHA: 688177), a China-based biopharmaceutical company, announced that its biosimilar version of...
Sandoz Receives FDA Clearance for First Biosimilar to Biogen’s Tysabri
The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has received regulatory clearance from the US...
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...
Biogen and Sage Therapeutics Receive FDA Approval for Postpartum Depression Treatment Zurzuvae
Biogen Inc., (NASDAQ: BIIB) and its partner Sage Therapeutics Inc., (NASDAQ: SAGE) have announced that...
Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal
US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully...
Biogen’s Q2 2023 Report Reveals Struggles with Aduhelm and 1,000 Job Cuts
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...
InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Biogen and Tsinghua University Launch Three-Year Neuroscience Collaboration
US-based Biogen (NASDAQ: BIIB) and the School of Pharmaceutical Sciences at Tsinghua University have announced...
InnoCare Pharma’s Orelabrutinib Placed on Partial Clinical Hold by FDA
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced that the US FDA has placed...
Eisai and Biogen Initiate BLA in China for Alzheimer’s Therapy Lecanemab
Japan-based Eisai Co., Ltd (TYO: 4523) and its US co-development partner Biogen Inc. (NASDAQ: BIIB)...